Skip to main content
Evidence Snapshot

Ephrin type-B receptor 4

CHEMBL5147 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5147
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ephrin type-B receptor 4 as ChEMBL target CHEMBL5147, mapped to UniProt P54760. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ephrin type-B receptor 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5147
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P54760
Ephrin type-B receptor 4
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Ephrin type-B receptor 4 matters

As of 2026-09-14

Ephrin type-B receptor 4 is reviewed as Ephrin type-B receptor 4 (UniProt P54760); Ephrin type-B receptor 4 shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 21 approved drugs, 2536 compounds, and 427 assays, with lead potency reaching pChEMBL 9.9.

Disease context
non-small cell lung carcinoma

Ephrin type-B receptor 4 shows late clinical disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include TESEVATINIB.

Start review with non-small cell lung carcinoma because it currently carries late clinical support. Linked drugs include TESEVATINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 21 approved drugs, 2536 compounds, and 427 assays for this target. The dominant activity type is IC50. CHEMBL4100979 is the current potency anchor at pChEMBL 9.9.

Use CHEMBL4100979 as the tractability anchor when discussing potency (pChEMBL 9.9).

Activity source · ChEMBL 36 via Core Engine
21 approved pChEMBL 9.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Ephrin type-B receptor 4 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P54760, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why non-small cell lung carcinoma is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2536
Total Compounds
427
Total Assays
21
Approved Drugs
IC50: 1541.0, KI: 6.0, EC50: 4.0, KD: 390.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4100979
 9.9 IC50 —
No preferred name
CHEMBL4469077
 9.8 IC50 —
No preferred name
CHEMBL1336
 9.7 IC50 Approved
No preferred name
CHEMBL4459732
 9.6 IC50 —
No preferred name
CHEMBL4069517
 9.6 IC50 —

Approved Drugs

Structure Compound First Approval
TIVOZANIB
CHEMBL1289494
 2017
BOSUTINIB
CHEMBL288441
 2012
CRIZOTINIB
CHEMBL601719
 2011
VANDETANIB
CHEMBL24828
 2011
NILOTINIB
CHEMBL255863
 2007
DASATINIB
CHEMBL5416410
 2006
DASATINIB ANHYDROUS
CHEMBL1421
 2006
SORAFENIB
CHEMBL1336
 2005
GEFITINIB
CHEMBL939
 2003
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5147